Compare Fidelity National Information Servcs Inc (FIS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Twist Bioscience Corp — how do they compare? Fidelity National Information Servcs Inc trades at $42.08 (market cap $21.24B), while Twist Bioscience Corp trades at $89.45 (market cap $5.76B). The key difference: Fidelity National Information Servcs Inc is far larger — about 3.7× Twist Bioscience Corp's market cap, and Fidelity National Information Servcs Inc pays a 4.09% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FIS | TWST | |
|---|---|---|
Market Cap | $21.24B | $5.76B |
Sector | Technology | Health |
52-Week High | $81.94 | $102.88 |
52-Week Low | $37.72 | $24.16 |
Enterprise Value | $41.63B | $5.69B |
Dividend Yield | 4.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.02, up 3.54% today, with a bearish technical signal but strong analyst support. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a consensus price target of $52.57. Recent news highlights innovation in AI and cloud banking, though cash flow trends and debt levels warrant monitoring.
The outlook is cautiously optimistic with potential upside from earnings growth and strategic initiatives, balanced by risks from competitive pressures and financial leverage. Investor sentiment is positive driven by analyst buy ratings and recent business wins, but volatility may persist near-term.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
